NORTHWEST BIOTHERAPEUTICS INC 8-K

What Happened

• Northwest Biotherapeutics, Inc. announced it completed the acquisition of Advent BioServices Ltd. (a UK contract development and manufacturing organization) on October 24, 2025. Advent had been providing development, manufacturing, cryostorage and distribution services for Northwest’s DCVax® product platform and is now a wholly owned subsidiary.
• The total consideration is approximately $10.2 million: a purchase price of about $1.9 million (≈£1.4M) plus payment of outstanding accounts payable of about $8.3 million for services provided prior to the acquisition. Certain excluded payables of roughly $0.7 million were retained by the seller.

Key Details

• Closing date: October 24, 2025; acquisition agreement dated August 27, 2025.
• Payment terms: consideration payable in installments over two years starting three months after closing; unpaid installments accrue interest at 7.5% annually; payments may accelerate after regulatory approval of DCVax‑L.
• Equity adjustments: Northwest received back 12.0 million common shares and 5.5 million stock options previously issued to Advent; the returned shares were retired and the options cancelled.
• Related‑party and disclosure notes: the seller (Toucan Holdings LLC) is controlled by Northwest’s Chair/CEO/President Linda Powers, making this a related‑party transaction that was reviewed under the company’s policies. The SEC granted a waiver under Rule 3‑13 of Regulation S‑X, so the company did not provide Advent’s Rule 3‑05 financial statements or pro forma financial information in the filing.

Why It Matters

• The acquisition brings Northwest’s outsourced CDMO partner in‑house, securing control over development, manufacturing, cryostorage and distribution for the DCVax platform—functions that are operationally important for clinical programs and future commercialization.
• Financially, the company assumed or agreed to pay approximately $8.3M of historic payables and faces installment obligations (with 7.5% interest) totaling roughly $10.2M, which may affect cash flow and liabilities over the next two years and could accelerate if DCVax‑L receives regulatory approval.
• The related‑party nature of the deal and the SEC waiver mean investors have limited third‑party financial detail about Advent and no pro forma disclosures in this filing, which reduces available historical financial context for evaluating the transaction.